SpyBiotech are pioneering a powerful new approach to generate vaccines.
The company was spun out from the University of Oxford in early 2017, supported by Oxford Sciences Innovation and Google Ventures.
Conventional approaches to generate vaccines are slow and often ineffective.
SpyBiotech’s proprietary protein superglue technology, SpyTag/SpyCatcher, makes it possible to produce vaccines more quickly, cheaply and effectively. SpyBiotech are harnessing this unique platform to generate vaccines to major human and veterinary health challenges for Europe, the US and worldwide.
SpyTag technology has application across a range of diseases and vaccine platforms. We are keen to partner with other companies to develop these opportunities, so please get in touch.